Background: The DESolve Bioresorbable Coronary Scaffold is a novel drug-eluting device combining a PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor, has demonstrated potent antiproliferative properties in two First-in-Man (FIM) trials using Elixir's metallic coronary stents. The drug dose is 3 mcg per mm of scaffold length. We aimed to present the IVUS results of the first-in-man evaluation of this novel scaffold.
